Is genetic testing required while taking osimertinib/osimertinib?

Yes, genetic testing is usually required for patients treated with Osimertinib (Osimertinib) to treat non-small cell lung cancer (NSCLC). Osimertinib/Osimertinib is mainly used to treat EGFR (epidermal growth factor receptor) mutation-positive NSCLC patients, which is a common molecular marker of lung cancer. Genetic testing can help determine whether a patient carries an EGFR mutation and thus determines whether he or she is a candidate for targeted therapy with osimertinib/osimertinib. For patients with EGFR mutation-positive, osimertinib/osimertinib can significantly improve the therapeutic effect and prolong progression-free survival and overall survival. Therefore, genetic testing is very important to determine the individualization and precision of treatment options. Generally speaking, doctors will recommend genetic testing after the diagnosis of NSCLC is confirmed to determine whether there is an EGFR mutation to guide subsequent treatment options. If a patient is diagnosed as EGFR mutation-positive, osimertinib may be recommended as a first-line treatment option. Therefore, genetic testing can help doctors and patients work together to formulate a treatment plan that is most suitable for individual conditions and improve treatment effects and quality of life.